Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Wake, B, Hyde, C, Bryan, S, Barton, PM, Song, F, Fry-Smith, A and Davenport, C (2002) Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technology Assessment, 6 (3). pp. 1-85. ISSN 2046-4924

Full text not available from this repository. (Request a copy)
Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: EPrints Services
Date Deposited: 25 Nov 2010 11:11
Last Modified: 23 Jan 2019 13:46
URI: https://ueaeprints.uea.ac.uk/id/eprint/13890
DOI:

Actions (login required)

View Item